Mural Oncology Statistics
Share Statistics
Mural Oncology has 17.06M shares outstanding. The number of shares has increased by 2.09% in one year.
| Shares Outstanding | 17.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.67% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.55M |
| Failed to Deliver (FTD) Shares | 268 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 412.86K, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 412.86K |
| Short % of Shares Out | 2.42% |
| Short % of Float | 2.66% |
| Short Ratio (days to cover) | 3.85 |
Valuation Ratios
The PE ratio is -0.48 and the forward PE ratio is -0.69.
| PE Ratio | -0.48 |
| Forward PE | -0.69 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.37 |
| P/FCF Ratio | -0.5 |
| PEG Ratio | n/a |
Enterprise Valuation
Mural Oncology has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.56, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.56 |
| Quick Ratio | 9.56 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.26 |
| Cash Flow / Debt | -31.85 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.79% and return on capital (ROIC) is -74.15%.
| Return on Equity (ROE) | -0.79% |
| Return on Assets (ROA) | -0.69% |
| Return on Capital (ROIC) | -74.15% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.94M |
| Employee Count | 107 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 12.16M |
| Effective Tax Rate | -0.06 |
Stock Price Statistics
The stock price has increased by 5.54% in the last 52 weeks. The beta is 0, so Mural Oncology's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 5.54% |
| 50-Day Moving Average | 3.61 |
| 200-Day Moving Average | 3.65 |
| Relative Strength Index (RSI) | 45.75 |
| Average Volume (20 Days) | 143.38K |
Income Statement
In the last 12 months, Mural Oncology had revenue of $0 and earned -$207.45M in profits. Earnings per share was $-12.43.
| Revenue | 0 |
| Gross Profit | -2.57M |
| Operating Income | -194.64M |
| Net Income | -207.45M |
| EBITDA | -192.72M |
| EBIT | - |
| Earnings Per Share (EPS) | -12.43 |
Balance Sheet
The company has $270.85M in cash and $15.01M in debt, giving a net cash position of $255.84M.
| Cash & Cash Equivalents | 270.85M |
| Total Debt | 15.01M |
| Net Cash | 255.84M |
| Retained Earnings | -30.86M |
| Total Assets | 203.27M |
| Working Capital | 158.88M |
Cash Flow
In the last 12 months, operating cash flow was -$194.25M and capital expenditures -$3.45M, giving a free cash flow of -$197.70M.
| Operating Cash Flow | -194.25M |
| Capital Expenditures | -3.45M |
| Free Cash Flow | -197.70M |
| FCF Per Share | -11.85 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -343.37% |
| FCF Yield | -320.56% |
Analyst Forecast
The average price target for MURA is $16.5, which is 355.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.5 |
| Price Target Difference | 355.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -1.15 |
| Piotroski F-Score | 3 |